Managed Care Weekly Digest
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Cyberonics provides patient access and outcomes update for VNS therapy
October 9th, 2006
Cyberonics, Inc. (CYBX) provided an update on the access to VNS Therapy for patients with treatment-resistant depression (TRD) and the outcomes of patients with TRD treated with VNS Therapy since FDA approval in July 2005. "Since FDA approval in July 2005, more than 3,000 psychiatrists have sought Cyberonics' assistance with patient education and qualification, and insurance verification and prior authorization for more than 13,000 patients with TRD," commented Shawn P. Lunney, Cyberonics' vice president of Market Development. "To date, more than 1,800 TRD patients have begun their treatment with VNS Therapy, while some 7,000 patients with TRD have been denied access to...
Source: Managed Care Weekly Digest (2006-10-09)
|
